

Irina Kulikovskaya

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8604282/publications.pdf>

Version: 2024-02-01

18
papers

5,247
citations

471509

17
h-index

839539

18
g-index

19
all docs

19
docs citations

19
times ranked

6691
citing authors

#	ARTICLE	IF	CITATIONS
1	Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. <i>Nature Medicine</i> , 2018, 24, 563-571.	30.7	1,150
2	CRISPR-engineered T cells in patients with refractory cancer. <i>Science</i> , 2020, 367, .	12.6	872
3	NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. <i>Nature Medicine</i> , 2015, 21, 914-921.	30.7	728
4	Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. <i>Nature</i> , 2018, 558, 307-312.	27.8	574
5	Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. <i>Nature Medicine</i> , 2018, 24, 1499-1503.	30.7	459
6	Decade-long leukaemia remissions with persistence of CD4+ CAR T cells. <i>Nature</i> , 2022, 602, 503-509.	27.8	369
7	Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer. <i>Cancer Immunology Research</i> , 2017, 5, 1152-1161.	3.4	309
8	PSMA-targeting TGF β 2-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial. <i>Nature Medicine</i> , 2022, 28, 724-734.	30.7	171
9	Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. <i>JCI Insight</i> , 2018, 3, .	5.0	140
10	Effect of MyBP-C Binding to Actin on Contractility in Heart Muscle. <i>Journal of General Physiology</i> , 2003, 122, 761-774.	1.9	109
11	Supraphysiologic control over HIV-1 replication mediated by CD8 T cells expressing a re-engineered CD4-based chimeric antigen receptor. <i>PLoS Pathogens</i> , 2017, 13, e1006613.	4.7	106
12	Retroviral and Lentiviral Safety Analysis of Gene-Modified T Cell Products and Infused HIV and Oncology Patients. <i>Molecular Therapy</i> , 2018, 26, 269-279.	8.2	90
13	BET bromodomain protein inhibition reverses chimeric antigen receptor extinction and reinvigorates exhausted T cells in chronic lymphocytic leukemia. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	45
14	Efficient Trafficking of Chimeric Antigen Receptor (CAR)-Modified T Cells to CSF and Induction of Durable CNS Remissions in Children with CNS/Combined Relapsed/Refractory ALL. <i>Blood</i> , 2015, 126, 3769-3769.	1.4	40
15	Posterior Reversible Encephalopathy Syndrome (PRES) after Infusion of Anti-Bcma CAR T Cells (CART-BCMA) for Multiple Myeloma: Successful Treatment with Cyclophosphamide. <i>Blood</i> , 2016, 128, 5702-5702.	1.4	31
16	Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CTL019) in Conjunction with Salvage Autologous Stem Cell Transplantation for Advanced Multiple Myeloma. <i>Blood</i> , 2016, 128, 974-974.	1.4	28
17	Efficacy and Safety of Humanized Chimeric Antigen Receptor (CAR)-Modified T Cells Targeting CD19 in Children with Relapsed/Refractory ALL. <i>Blood</i> , 2015, 126, 683-683.	1.4	22
18	Autologous CD4 ⁺ T Lymphocytes Modified with a Tat-Dependent, Virus-Specific Endoribonuclease Gene in HIV-Infected Individuals. <i>Molecular Therapy</i> , 2021, 29, 626-635.	8.2	3